Type I interferons (e.g. IFNa2b) have been successfully used to treat a variety of hematological malignancies, but have not been efficacious for treatment of most solid tumors. We tested the hypothesis that delivery of type I interferon utilizing recombinant adenovirus (rAd) vectors may improve treatment efficacy of metastatic carcinomas by providing increased interferon exposure resulting from continuous transgene expression. Treatment of mice with a rAd-vector expressing hybrid-IFN (rAd-IFNa2a1) inhibited 4T1 mammary carcinoma tumor growth and induced tumor regression in a dose-dependent manner. Moreover, rAd-IFNa2a1 treatment reduced hepatic and pulmonary metastatic burden. A comparison of local and systemic routes of administration demonstrated that intratumoral delivery of rAd-IFNa2a1 was sufficient for inhibition of tumor growth. Moreover, it reduced toxicity associated with high-dose systemic IFNa2a1 exposure. Interestingly, antitumor activity following intratumoral treatment was due, in part, to the immunostimulatory capacity of the rAd vector component. Furthermore, systemic administration of rAd-IFNa2a1 potentiated the immunotherapeutic effect induced by local intralesional delivery of empty-rAd vector. These results suggest continuous interferon-a exposure may provide improved antitumor responses for metastatic carcinomas. Additionally, immunostimulatory responses induced by rAd-IFNa2a1 may mitigate the immune-evasive tumor microenvironment.
Introduction
Interferon-a protein (IFNa) is pleiotropic cytokine demonstrated to have antiviral, antiproliferative and immunomodulatory activities. [1] [2] [3] [4] It induces the expression of more than 300 genes 5 including transcription of genes resulting in cell-cycle arrest and apoptosis (JAK-STAT pathway). 3 Interferon-a modulates cancer cell growth, differentiation, intracellular signaling, and causes both apoptotic and nonapoptotic cell death. [6] [7] [8] Interferon-a has been successfully used to treat a variety of hematological malignancies, but has had limited success in the treatment of solid tumors. We reasoned that sustained exposure to IFNa might alter its pharmacodynamics and may improve therapeutic efficacy. Therefore, we used a recombinant adenoviral vector (rAd) to deliver interferon to target tissues. Here, the therapeutic potential of IFNa to treat metastatic carcinoma was evaluated using the transplantable 4T1 mammary carcinoma model in syngeneic BALB/c mice. This tumor model shares many characteristics with human malignant breast carcinomas. [9] [10] [11] [12] The 4T1 line is highly tumorigenic, poorly immunogenic, and spontaneously metastasizes via the lymphatics to the lungs, liver and bone. [9] [10] [11] [12] Most preclinical studies of IFNa anticancer therapy have been carried out utilizing human IFNa isoforms to treat immunocompromised mice bearing human tumor xenografts. A limitation of human xenograft models is that they fail to address the role IFNa plays in host cellular responses, as most isoforms of human IFNa do not functionally interact with murine IFN receptors. On the other hand, hybrid human IFNa2a1 binds to murine IFN receptors, 13 and can elicit responses in mouse derived tumor cells as well as in host derived cells comprising the tumor stroma and cells of the immune system. This is particularly important for analyzing the effects of IFNa for treatment of malignant carcinomas since processes promoting invasion and metastasis are dependent on host responses induced by the tumor microenvironment. 14 In this report, we characterize the direct effects of IFNa on cell cycle and proliferation of 4T1 mammary carcinoma cells, as well as, the effects of extended IFNa exposure on tumor growth and metastases in mice bearing transplanted 4T1 tumors. Treatment with rAd-IFNa2a1 resulted in a dose-dependent tumor growth inhibition, as well as, a significant reduction in spontaneous metastases to target organs (lung and liver). In addition, we assessed the relative antitumor efficacy and toxicity in tumor bearing mice following treatment using different routes of administration. Studies were performed in immunocompetent and immunocompromised mice to assess the impact of rAd-IFNa2a1 immunostimulatory function on antitumor efficacy. Additionally, we investigated the relative contributions of the rAd vector and IFNa2a1 transgene product for inducing tumor growth inhibition and mitigation of metastatic burden. The results presented herein demonstrate the potential for extending the range of cancer therapy indications for IFNa to include malignant carcinoma through improvements in pharmacokinetics.
Materials and methods

Animals and reagents
Female BALB/c ByJ mice were obtained from The Jackson Laboratory (Bar Harbor, ME) and C.B-17 SCID-BEIGE (SCID-BEIGE) mice were obtained from Taconic (Germantown, NY) and were used at 8-12 weeks of age. All experiments were performed with strict adherence to the US Public Health Service Policy on Humane Care and use of Laboratory Animals.
Human IFNa ELISA kits were purchased from PBL Laboratories (Piscataway, NJ). The adenoviral constructs used in this study were rAd-empty control (ZZCB) and rAd-IFNa2a1 (IHCB). 15 Virus preparations were produced in 293 packaging cell lines and purified by column chromatography. 16 Virus particle concentration was quantified by anion exchange chromatography. 17 Cell proliferation assays Cell cycle progression, proliferation and apoptosis were measured in unmodified 4T1 cells, cells infected with various concentrations of rAd-empty or rAd-IFNa2a1 and cells cultured in medium containing various concentrations of IFNa2a1 protein. Adenovirus-vector infected cells were washed after a 1 h pulse and then analyzed at various times following transduction. Cells treated with IFNa2a1 protein were cultured in the presence of the protein for the entire treatment schedule. After 48 h of treatment, cells were pulse labeled with 10 mM bromodeoxyuridine (BrdU) for 2 h. Cells were then harvested for bivariate BrdU/DNA flow cytometric analysis by fixation in 70% ethanol, followed by digestion with 0.08% pepsin for 30 min at 371C. Fixed cells were centrifuged at 1500 r.p.m., and resuspended in 2 N HCl, incubated at 371C for 20 min, followed by addition of 1 M sodium borate. Cells were then washed in IFA/Tween-20 (0.1 M HEPES, 0.05% sodium azide, 0.5% Tween-20, 5% FBS, 0.15 M NaCl), and anti-BrdU antibody (Becton-Dickinson), diluted 1:10 in IFA without Tween-20, was added for 30 min. Cells were washed in IFA/Tween-20, and incubated in IFA/ Tween-20/RNase for 15 min at 371C and stained with propidium iodide (50 mg/ml). Cells were analyzed by flow cytometry (FACS) on the FL-1 channel for measurement of BrdU-uptake and the FL-2 channel for measurement of DNA content (propidium iodide intercalation). Cell proliferation was assessed at 24, 48 and 72 h following initiation of treatment by comparing cell counts in the various treatment groups using a Particle Count and Size analyzer (Beckman Coulter). The summary of bivariate analysis for cells cycle and proliferation in tabular form are reported as the mean of duplicate samples7the range.
In vivo tumor studies The 4T1 cell line was a kind gift from Fred Miller at the Barbara Ann Karamanos Cancer Institute, Detroit MI. Cells were cultured in Dulbecco's modified Eagle's medium (BioWhittaker, Walkersville, MD) supplemented with 10% fetal bovine serum (Hyclone, Logan, UT). Mice were implanted subcutaneously in the left flank with 3 Â 10 5 4T1 cells and the tumors were allowed to grow for 8 days. Mice were measured and sorted to ensure an equal distribution of mice bearing tumors of similar size (generally 25-50 mm 3 ) between experimental and control groups. Tumor sizes were measured with Vernier calipers in three dimensions (width, length and depth) and tumor volume was calculated assuming a spherical geometry, with radius equal to a half of the average tumor dimension, using the formula:
). Prior to initiation of treatment, mice were randomized utilizing the LABCAT software based on tumor volume and assigned to the various treatment groups to ensure equal distribution. Tumors were measured at least three times per week along with mouse total body weight to evaluate the effects of treatment on tumor growth and host weight. All the data were acquired and initially analyzed using LABCAT software. The mean tumor volume or total body weight versus time was plotted with standard error of means for each treatment group. Further statistical analysis was carried out as described below.
Treatments were initiated on day 8 following the tumor implantation. Systemic administration of viral vectors was performed by single intravenous injection of various doses in a 200 ml volume via tail vein. Intratumoral injection was performed in a 100 ml volume into multiple sites within the subcutaneous tumor three times weekly for 1 or 2 weeks, as indicated.
Metastasis measurements
Organs were fixed in 10% buffered formalin. Prior to paraffin embedding, the number of pulmonary metastatic lesions on lung surfaces was quantified under a dissecting microscope using Â 2-4 magnification. Organs were embedded in paraffin, sectioned and stained with H&E. Invasion into the lung parenchyma was observed as 4T1 pulmonary metastatic lesions progressed. Therefore, further analysis of pulmonary metastatic lesions was performed using morphometric analysis to quantify the relative area of metastatic lesions through four serial coronal sections spaced 500 mm apart using Image-Pro Plus software. The sums of the areas comprising the metastatic lesions through the coronal sections were used to compare pulmonary metastatic burden between animals and treatment groups. Liver micrometastases were counted under Â 20 magnification in seven fields using a Nikon eclipse E600 microscope, the cumulative number of metastases in 3-4 liver sections was used for comparative analysis.
Protein isolation from tumor
Tumor tissue samples were placed in lysate buffer and subjected to three freeze-thaw cycles. Lysates were centrifuged to remove debris and supernates were collected for determination of IFNa2a1 protein concentration by ELISA (PBL Biomedical Laboratories).
Statistical analysis
Two-way ANOVA tests (GraphPad Prism software) were used to quantify statistical differences between treatment groups for comparisons of primary tumor volume, percent (%) change in weight, number of liver metastases, number of lung surface metastases and area of lung metastases. One-way ANOVA followed by Tukey's multiple comparison test was used to assess statistical significance in tumor size or weight changes within the same treatment group.
Results
Interferon-a2a1 inhibits 4T1 cell growth in vitro
The capacity of type I interferons to inhibit tumor cell proliferation or induce apoptosis varies depending on the particular cell line. 18 -27 Therefore, we tested the capacity of hybrid IFNa to modulate cell cycle progression, proliferation and apoptosis in 4T1 mammary carcinoma cells. Analysis was carried out in unmodified 4T1 cells, cells infected with various concentrations of rAd-empty or rAd-IFNa2a1 and cells cultured in medium containing various concentrations of IFNa2a1 protein.
As shown using bivariate BrdU/DNA flow cytometric analysis in Figure 1 and Table 1 , we did not observe a change in BrdU and PI staining in 4T1 cells infected with 3 Â 10 8 and 3 Â 10 9 particles per ml of the rAd-empty control vector. In contrast, the percentage of cells in S-phase, as indicated by the relative BrdU incorporation (Figure 1a ), increased in a dose-dependent manner in response to either rAd-IFNa2a1 vector transduction, or treatment with hybrid IFNa2a1 protein (summarized in Table 1 ), indicative of an S-phase delay. Moreover, analysis of PI staining for DNA content ( Figure 1b , Table 1 ) showed no increase in the number of cells in the subG0/G1 region at 48 h following rAd-IFNa2a1 transduction or hybrid IFN treatment, demonstrating that hybrid IFNa2a1 did not induce apoptosis at that time point. Thus, IFNa2a1 appeared to cause a pile-up of cells in S-phase, suggesting a possible block at the check point for cells progressing from S-phase to G2/M.
Cell counts were carried out on untreated, rAd-empty vector transduced, rAd-IFNa2a1 transduced and IFNa2a1 protein treated 4T1 cells to assess the effect on cell proliferation. Proliferation was inhibited by about 30-40% when cultured in the presence of IFNa2a1 protein or transduced with rAd-IFNa2a1 vector (Table 1) . Thus, the primary direct effect of IFNa2a1 on 4T1 cells was a partial inhibition of proliferation associated with an inhibition of cell cycle progression in S-phase.
Treatment with rAd-IFNa2a1reduced 4T1 tumor size in immunocompetent mice in a dose-dependent manner While the direct effect of IFNa2a1 on proliferation could be assessed in vitro, inhibition of tumor growth and metastasis, which is dependent on modulation of host responses that promote malignant tumor growth, was evaluated in therapeutic tumor models. BALB/c mice were implanted subcutaneously (s.c.) in the left flank with 3 Â 10 5 4T1 mammary carcinoma cells and monitored for tumor growth. Treatment was initiated on day 8 posttumor implantation. Recombinant adenoviral vectors were administered, at various doses, by a single intravenous (i.v.) infusion, by multiple intratumoral (i.t.) injections given over a 1-or 2-week schedule, or using a combination of a single i.v. infusion and multiple i.t. injections.
A dose response study was carried out, using the combination of single i.v. and four i. 11 PN using the combination of i.v. þ i.t. administration were remarkable, there were limitations due to adverse effects of high IFNa2a1 doses (see Figure 3 ). While the adverse effects were partially mitigated by truncating the time of treatment to 1 week, we further investigated the use of different routes of administration to mitigate adverse effects, using the 1 Â 10 10 PN or 5 Â 10 10 PN doses (see Figure 2b and c). Moreover, we investigated the relative contribution of the rAd-vector component for observed antitumor effects.
As mentioned above, we detected no significant effect of rAd-empty control vector on cell cycle progression and proliferation in vitro. Interestingly, we observed a dosedependent effect on tumor growth induced by the rAdempty vector treatment compared to PBS control in BALB/c mice (Figure 2a-c) . While rAd had a modest, but not statistically significant, inhibitory effect on the primary tumor growth at 1 Â 10 10 PN dose (Figure 2b ), at higher doses its effect was more substantial (Po0.02, Figure 2a and c). However, a significant transgene- 
Therapy effect on body weight
We measured body weights in mice treated with various doses of rAd-IFNa2a1 by the different administration routes as a measure of adverse responses to the therapy. No significant weight loss was observed in BALB/c mice administered 1 Â 10 10 PN of rAd-empty or rAd-IFNa2a1 (Figure 3a and b) . On the other hand, we observed a transient weight loss as well as ruffled fur in all mice treated with higher doses (5 Â 10 10 or 1 Â 10 11 PN) of rAd-IFNa2a1 by i.v. route (Figure 3a and c) . A weight gain was observed starting at about 6 days post-i.v. infusion with rAd-IFNa2a1, when neutralizing immune responses to adenovirus were approaching peak levels. The adverse responses seemed to require systemic exposure to high amounts of IFNa2a1 as mice that received high doses of rAd-IFNa2a1 by the i.t. only route appeared normal and did not show significant weight loss. Moreover, little weight loss was observed in mice treated i.v. (or i.v. þ i.t.) with control rAd-empty vector. Thus, the toxicity observed after intravenous delivery of high doses of rAd-IFNa2a1 was primarily due to hybrid interferon transgene expression and not adenovirus.
In a manner similar to BALB/c mice that received high doses of rAd-IFNa2a1 i.v., SCID-BEIGE mice treated i.v. or i.v. þ i.t. with 1 Â 10 10 PN of rAd-IFNa2a1 were ruffled and had a marked loss of weight (Po0.0001, Figure 3d ). The adverse effects in SCID-BEIGE mice were also caused by high systemic exposure to IFNa2a1, as no apparent toxicity was observed in mice treated with rAd-IFNa2a1 by the i.t. only route or in mice that received empty rAd.
Hybrid interferon reduced metastatic burden in mice
The 4T1 mammary carcinoma is highly metastatic giving spontaneous rise to pulmonary and hepatic metastases in virtually all animals implanted with the tumor by s.c. route. The results in Figure 4a show that treatment with rAd-IFNa2a1 by both i.v. and i.t. routes reduced metastasis in 4T1 tumor bearing BALB/c mice in a dose-dependent manner (Po0.0001). We observed a three-to five-fold reduction in pulmonary and hepatic metastatic burden in mice treated with 10 10 PN of rAdIFNa2a1 (Figure 4a Interferon-a treatment of metastatic carcinoma E Brin et al
In contrast, treatment with 5 Â 10 10 PN of rAd-IFNa2a1 by i.t. only route induced a highly significant (Po0.0001) reduction in metastasis.
In SCID-BEIGE mice treated with 1 Â 10 10 PN of rAdIFNa2a1 by i.t. route, only superficial metastases were observed on the lung surface and no metastatic lesions could be detected by histological analysis of serial sections through the lungs (Figure 4d , Po0.001). Liver metastases were greatly reduced (more than five-fold, Po0.01) in these mice compared to PBS controls (Figure 4d ). Emptycontrol adenoviral vector did not induce a statistically significant effect on lung metastases in SCID-BEIGE Interferon-a treatment of metastatic carcinoma E Brin et al mice. In contrast, rAd-empty vector significantly reduced metastasis to the liver, especially when delivered by i.v. route (Po0.001) (Figure 4d) .
Pharmacokinetics of the transgene hybrid interferon expression
We quantified IFNa2a1 serum and tumor tissue concentrations to determine the relative correlation of the observed antitumor effects, as well as effects on body weight with local and systemic hybrid IFN exposure. Serum IFNa2a1 increased in a dose-dependent manner in mice administered 1 Â 10 10 , 5 Â 10 10 and 1 Â 10 11 PN of rAd-IFNa2a1 (Figure 5a ). On day 1 after initiation of the treatment, there was no neutralizing antibody response to rAd vector (rAdNAb) (data not shown) and transgene levels were very high (Figure 5a ). While rAd-IFNa2a1 was administered i.t. two more times on days 2 and 5 after the initial rAd-IFNa2a1 i.v. and i.t. treatments, on day 6 serum IFNa2a1 levels decreased sharply compared to day 1 postinitial treatment ( Figure 5a ). Decreased expression coincided with high rAd-specific nAb titers induced by all tested doses (10 10 , 5 Â 10 10 or 10 11 PN) (data not shown) similar to nAb responses induced by rAd injection that we have described in prior reports. 28 We and others 29 have observed that while additional expression can be achieved following readministration by intratumoral route, the expression levels are markedly lower as compared to the first administration. However, the capacity for readministration to result in induction of additional expression diminishes with each round and is associated with a boost in the rAd-specific nAb responses as well as the cellular immune response to rAd-transduced cells further promoting a reduction in transgene expression.
As expected, after single treatment, IFNa2a1 expression levels were the highest in mice administered a combination of i.v. and i.t. rAd-IFNa2a1 as compared to those that received i.v. only or i.t. only delivery (Figure  5b and c) . Treatment by i.t. only injection resulted in higher tumor and lower serum IFNa2a1 concentrations compared to i.v. delivery. IFNa2a1 levels were greatly diminished on day 3 post-treatment in both serum and tumors. We then assessed the pharmacokinetics for serum and tumor IFN concentrations over a full treatment regimen consisting of multiple i.t. injections administered three-times weekly for 2 weeks. We did this since the antitumor efficacy results described above indicated that i.t. only administration of rAd-IFNa2a1 at doses of 5 Â 10 10 particles and above was sufficient to induce tumor growth inhibition. Moreover, we did not observe overt toxicity when mice were dosed multiple times by the i.t. only route. As shown in Figure 5d , IFNa2a1 concentrations measured in tumors were markedly higher than those observed in the sera and remained elevated for a longer period of time. Levels of hybrid-IFN in both serum and tumors progressively declined by day 8 and were below detectable range on day 12 after the treatment initiation despite continued i.t. injection through day 13.
Discussion
Interferon-a was the first biological agent approved by the FDA for treatment of malignancy (hairy cell leukemia 1986).
1 Now, it is widely used in a clinic as a protein therapeutic for treatment of various cancers 30 (hairy cell Figure 3 Effect of hybrid interferon expressing rAd-vectors on body weight of tumor bearing BALB/c and SCID-BEIGE mice. Mice were treated and measured as described in Figure 2 . Each curve shows the mean body weight (7s.e.m.) of 4-9 mice per treatment group over time.
Interferon-a treatment of metastatic carcinoma E Brin et al leukemia, chronic myeloid leukemia, myeloma, lymphomas, renal cell carcinoma, Kaposi's sarcoma, melanoma, etc.) as well as for various viral infections (hepatitis B and C, herpetic keratitis, papillomas). In vitro, IFNa has been shown to inhibit proliferation of various cell lines by inducing cell accumulation in S-phase. [25] [26] [27] Our results concur with these observations as 4T1 cells were accumulating in S-phase, but not undergoing apoptosis after exposure to human hybrid interferon protein or rAd-IFNa2a1 (Figure 1) . These results suggest that IFNa2a1 has a direct antiproliferative effect on the 4T1 cells but does not induce cell death in the absence of additional stimuli. We extend these observations by examining the effects of IFNa2a1 treatment in tumor bearing mice, allowing examination of the pleotropic effects directly on tumor cells as well as on host responses, which contribute to malignant tumor growth and metastasis. Moreover, we present our findings for the Interferon-a treatment of metastatic carcinoma E Brin et al effect of various routes of administration and pharmacokinetics on relative antitumor efficacy and therapeutic index.
While interferon-a as a protein therapeutic has been shown to provide good efficacy in hematological malignancies, its use in solid tumors at tolerated doses has been limited. In the present study, we examined the possibility of expanding interferon-a therapeutic indications to include malignant carcinomas. Unmodified interferon-a protein has a short serum half-life characterized by a spike in serum concentration followed by rapid clearance. 31, 32 Here, we utilize rAd based vectors as a means to deliver IFNa2a1 and to avoid wide fluctuations in the protein levels associated with protein therapy. Interferon is expressed as secreted protein in rAd-transduced cells, thus providing both autocrine and paracrine signaling to receptor positive cells. The primary source of transgene expression in mice administered rAd-IFNa2a1 by intravascular route are hepatocytes 33, 34 and IFNa2a1 is transported to primary and metastatic tumor lesions via the circulatory system.
Intratumoral injection of rAd-IFNa2a1 resulted in a four-fold higher concentration of IFNa2a1 in the tumor as compared to intravascular administration and was highest in mice treated by both i.v. and i.t. routes ( Figure 5) . Moreover, the capacity to redose by i.t. route resulted in an extended expression and intratumoral IFNa2a1 exposure up to 12-days. These pharmacological results correlated with antitumor activity. That is to say, i.t. delivery resulted in significant antitumor activity using lower doses (i.e. 1 Â 10 10 particles) than could be achieved by i.v. route (Figure 2b ). Significant inhibition of tumor growth in mice treated by i.v. only route required doses of 5 Â 10 10 particles of rAd-IFNa2a1. Moreover, there was Interferon-a treatment of metastatic carcinoma E Brin et al no significant toxicity observed in mice that received i.t. only administration, even at the high dose (5 Â 10 10 PN) range. This correlates with lesser systemic exposure to IFNa2a1 after i.t. administration compared to i.v. Following i.v. delivery, serum concentrations of IFNa2a1 were on the order of seven-fold higher as compared to concentrations in the tumor and 13-fold higher as was achieved with i.t. delivery (1 day post-treatment) .
In addition to the inhibitory effect of rAd-IFNa2a1 therapy on primary tumor growth, we also observed a significant reduction of pulmonary and hepatic metastatic burden. Doses of 5 Â 10 10 particles of rAd-IFNa2a1 provided equivalent effects on metastatic burden as that achieved at the maximal 1 Â 10 11 particle dose (Figure 4a ). While optimal effect on metastatic burden was achieved using the combination of i.v. and i.t. route of administration (Figure 4a and b) , a significant decrease in metastatic burden could also be achieved following treatment with 5 Â 10 10 particles of rAd-IFNa2a1 by an i.t. only route (Figure 4c ). These results suggest optimal therapeutic index, for rAd vector based delivery at least, may be high dose intralesional treatment as we observed potent antitumor and metastasis responses without inducing overt toxicity observed in mice treated by systemic (i.v.) route.
Adenovirus gene therapy with another type I IFNIFNb has been shown to be efficacious in various preclinical tumor models. [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] 36, 40, 41, 45 and through activation of innate and adaptive immune responses. 36, 37, 40, 41, 47 On the other hand, systemic delivery of Ad-IFNb resulted in efficient hepatocyte transduction with the vector and potent liver metastases inhibition. 35, 46 An interesting distinction between the two type I IFNs is the relative essential role for the effect of IFNb on stimulation of immune cells as there was a loss of efficacy in tumor bearing SCID-BEIGE. 42 In contrast, we observed significant efficacy with tumor IFNa treatment in immunocomprimised mice, suggesting the induction of responses not dependent on T-lymphocyte function, were sufficient to elicit tumor growth inhibition. This is consistent with the observation that different type I interferons can elicit differential responses despite interaction with a common receptor. 48 Our results extend prior reports indicating that continuous expression of IFNa as achieved using rAdbased gene delivery may be beneficial to patients [49] [50] [51] [52] [53] by demonstrating an impact on metastatic burden as well as on the primary tumor. In part, this may be due to the capacity of interferon-a to modify host responses that support tumor growth as well as host immunity. 2, 4, 54, 55 Additional evidence for hybrid IFNa2a1 induced stimulation of immune cells could be discerned in the differential effect on tumors in immunocompetent BALB/c mice versus immunocomprimised SCID-BEIGE mice. Expression in BALB/c mice after four i.t. administrations of 5 Â 10 10 PN of rAd-IFNa2a1 over 1-week period was limited to about 7-10 days (Figure 5d ). However, tumor regression was observed in BALB/c mice starting at about 1-week after treatment suggesting extended pharmacodynamic effects resulting in tumor regression after expression had ceased in immunocompetent strains. Transgene expression was prolonged in immunocomprimised SCID-BEIGE mice resulting in a significantly longer effective dose as compared to immunocompetent BALB/c mice. For instance, in SCID-BEIGE mice, after the same treatment (for i.t. injections) but with lower 1 Â 10 10 PN dose, hybrid interferon was detected in serum as late as 2 weeks after the treatment initiation and was 4.770.8 ng/ml. Notwithstanding, high doses of rAdIFNa2a1 resulted in tumor regression to palpable scar tissue in BALB/c mice, whereas in SCID-BEIGE mice there was a significant inhibition of tumor growth but no regression. These results suggest treatment with hybrid interferon stimulates immunity associated with tumor regression providing an additive effect to its antiproliferative effects observed on 4T1 cells in vitro.
Antiproliferative effect of IFNa2a1 on 4T1 tumor in SCID-BEIGE mice was similar to but more dramatic than that observed in cell culture. While direct effect of IFNa2a1 on 4T1 cells is associated with cell growth inhibition in the absence of apoptosis, in SCID-BEIGE mice we cannot rule out the possibility of indirect effects of IFNa2a1 on host stromal cells and angiogenesis resulting in decreased tumor cell viability. Moreover, NK cells may have been stimulated by high concentrations of IFN as NK cells from SCID-BEIGE mice have been shown to be capable of tumor cell killing if stimulated, despite the diminished killing activity and capacity for degranulation induced by the beige mutation. 56 One potential advantage for utilizing rAd based gene therapy is the capacity to localize expression using intralesional injection, which greatly limits toxicity induced by systemic exposure. In addition, the proinflammatory nature of the vector seemed to induce an additive effect for antitumor activity in immunocompetent BALB/c mice. This rAd-induced antitumor effect was not observed in SCID-BEIGE mice, which are profoundly immunocompromised. Moreover, this rAd vector effect is augmented by systemic exposure to IFNa2a1 (Figure 2b and c) , which has immunostimmulatory function. 2, 4, 54, 55 However, immune responses to adenovirus also limit transgene expression. 57, 58 The limitation of immune clearance may be overcome with new less immunogenic generation of vectors. Additionally, regulatable and cell specific promoters may provide better control for targeting and manipulation of interferon expression. 15, 58 Interferon-a treatment of metastatic carcinoma E Brin et al
